Omada Health Begins Trading on Nasdaq at $19 per Share
Omada Health starts trading on Nasdaq at $19 per share, raising $150 million for chronic care management. ππΌ
June 9, 2025
Follow us
latest articles
Discover the newest research about AI innovations in π€ Personalized Medicine.
From Acquisition to Prognosis: The Role of AI in Cardiac Magnetic Resonance Imaging Evaluation of Ischemic Cardiomyopathy.
AI enhances cardiac MRI for ischemic cardiomyopathy, improving accuracy and prognosis. Key findings from PubMed article reviewed. π«π
June 9, 2025
Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma.
Deep learning predicts tumor response in large HCC: HTI shows 54.45% ORR vs. 21.65% for HAIC. ππ§¬
June 8, 2025
Leveraging Digital Twins for Stratification of Patients with Breast Cancer and Treatment Optimization in Geriatric Oncology: Multivariate Clustering Analysis.
AI-driven tool enhances breast cancer treatment for older adults, achieving 0.81 AUC in mortality prediction. ππ‘
May 26, 2025
Importance of Diverse Datasets for AI in Healthcare
Diverse datasets are crucial for AI in healthcare. They help reduce biases and improve treatment options globally. ππ
May 25, 2025
AI Algorithm Enhances Stent Healing Assessment
AI algorithm DeepNeo improves stent healing assessment, offering faster, accurate analysis of OCT images. π©Ίπ
May 14, 2025
DarioHealth Secures $50 Million in Debt Financing and Epicore Biosystems Expands Funding
DarioHealth secures $50 million in debt financing for chronic condition management. Epicore Biosystems expands funding to enhance sweat-sensing technology. π°π
May 2, 2025
Trends in the applications of artificial intelligence in fatty liver diseases.
AI’s role in fatty liver disease: 270 studies reveal diagnostic advancements, personalized therapies, and gene analysis potential. ππ§¬
May 2, 2025
Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer.
AI-driven MSI profiling in lung cancer shows 0.52% prevalence, high TMB, and potential for personalized immunotherapy. ππ¬
April 29, 2025
Novel endometrial receptivity test increases clinical pregnancy and live birth rates in patients with recurrent implantation failure: Secondary analysis of a prospective clinical trial.
Endometrial receptivity testing boosts clinical pregnancy rates by 22.78% in recurrent implantation failure cases. ππΆ
April 14, 2025